Bristol won’t seek faster Opdivo, Yervoy lung cancer drug approvals | International News Live Blog

https://internationalnewsliveblog.wordpress.com/2017/01/20/bristol-wont-seek-faster-opdivo-yervoy-lung-cancer-drug-approvals/

(Reuters) – Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer. http://internationalnewslive.com/bristol-wont-seek-faster-opdivo-yervoy-lung-cancer-drug-approvals/